MedTrace Logo

Efficacy of XP20B Following Bunionectomy Surgery

NCT00655291 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2008-10-08

No results posted yet for this study

Summary

The purpose of this study is to determine if XP20B is an effective treatment for the relief of pain following bunionectomy surgery.

Conditions

  • Acute Pain

Interventions

DRUG

XP20B

DRUG

Placebo

Sponsors & Collaborators

  • Xanodyne Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Keith Moore, PharmD · Xanodyne Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00655291 on ClinicalTrials.gov